-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
The contrast agent market has regained waves, and China Resources Shuanghe octafluoropropane lipid microsphere injection has been approved for marketing for the first time in China, and Hengrui gadolinium butrol injection has won the first imitation
in the United States.
According to data from Minai.
com, the sales of terminal contrast agents in China's public medical institutions in 2022H1 exceeded 6.
6 billion yuan, the product TOP10 iofodol injection ranked first for the first time, the three major products rose by more than 20%, the brand TOP10 foreign brands occupied 7 seats, and Hengrui 2 brands were on the list
.
At present, 11 varieties of contrast agents have been evaluated, and 2 major varieties have been hit
hard.
in the United States.
According to data from Minai.
com, the sales of terminal contrast agents in China's public medical institutions in 2022H1 exceeded 6.
6 billion yuan, the product TOP10 iofodol injection ranked first for the first time, the three major products rose by more than 20%, the brand TOP10 foreign brands occupied 7 seats, and Hengrui 2 brands were on the list
.
At present, 11 varieties of contrast agents have been evaluated, and 2 major varieties have been hit
hard.
Contrast agent TOP10! "One brother" changed owners, 5 major products rose by more than 10%
According to data from Minai.
com, in 2021, the sales scale of terminal contrast agents in China's urban public hospitals, county-level public hospitals, urban community centers and township health centers (referred to as China's public medical institutions) exceeded 17 billion yuan, a year-on-year increase of 13.
05%; In the first half of 2022, its sales scale exceeded 6.
6 billion yuan, down 22.
89% from the same period last year, showing a sharp decline
for the first time.
com, in 2021, the sales scale of terminal contrast agents in China's urban public hospitals, county-level public hospitals, urban community centers and township health centers (referred to as China's public medical institutions) exceeded 17 billion yuan, a year-on-year increase of 13.
05%; In the first half of 2022, its sales scale exceeded 6.
6 billion yuan, down 22.
89% from the same period last year, showing a sharp decline
for the first time.
Sales of terminal contrast agents in public medical institutions in China (: million yuan)
Source: Minai.
com Competition Pattern of Drug Terminals in China's Public Medical Institutions
com Competition Pattern of Drug Terminals in China's Public Medical Institutions
Among the top 10 contrast agent products, iodized salt X-ray contrast agent occupies 6 seats, iofosol injection, iodixanol injection, iopromide injection, iohexol injection, iopamol injection ranked in the top five, iofosol injection ranked first with sales of more than 1.
4 billion yuan, and the second ranked iodixanol injection sales exceeded 1 billion yuan
.
4 billion yuan, and the second ranked iodixanol injection sales exceeded 1 billion yuan
.
2022H1 Top 10 terminal contrast agent products in China's public medical institutions
Source: Minai.
com Competition Pattern of Drug Terminals in China's Public Medical Institutions
com Competition Pattern of Drug Terminals in China's Public Medical Institutions
From the perspective of sales growth rate, 4 products showed negative growth, and iodixanol injection and iohexol injection included in the fifth batch of centralized procurement plummeted by 57.
90% and 59.
85% respectively; 5 products rose by more than 10%, the sales of iofosol injection rose by 33.
54%, and iomepur injection and iopamol injection both rose by more than 20%.
90% and 59.
85% respectively; 5 products rose by more than 10%, the sales of iofosol injection rose by 33.
54%, and iomepur injection and iopamol injection both rose by more than 20%.
Among the top 10 contrast agent brands, Hengrui Pharmaceutical's iofofenol injection won the "sales crown" for the first time, with sales exceeding 1 billion yuan, while Bayer's iopromide injection and GE's iohexol injection ranked second and third
respectively.
The four brands increased significantly, Hengrui Pharmaceutical's iofodol injection and gabutetate glucosamine injection increased by 35.
6% and 25.
86% respectively, Boleco's iodomepur injection increased by 24.
94%, and Bayer's ioprocamide injection increased by 12.
59%.
respectively.
The four brands increased significantly, Hengrui Pharmaceutical's iofodol injection and gabutetate glucosamine injection increased by 35.
6% and 25.
86% respectively, Boleco's iodomepur injection increased by 24.
94%, and Bayer's ioprocamide injection increased by 12.
59%.
2022H1 Top 10 terminal contrast agent brands in China's public medical institutions
Source: Minai.
com Competition Pattern of Drug Terminals in China's Public Medical Institutions
com Competition Pattern of Drug Terminals in China's Public Medical Institutions
It is worth mentioning that foreign brands occupy 7 seats, GE Pharmaceutical, Bracco each have 3 brands on the list, Bayer has one brand on the list; The only domestic brands on the list are Hengrui Pharmaceutical's iofodol injection and gadolinate glucosamine injection, and Yangtze River Pharmaceutical's iodixanol injection
.
.
3 contrast agents have been collected, 2 star varieties have plummeted, and 1 billion varieties are under pressure
Due to the high technical barriers of contrast agents and the difficulty of consistency evaluation in the initial injection evaluation, it was not until May 12, 2020 that the first evaluated contrast agent was born - Si Taili was approved and regarded as having been evaluated
as a generic of Class 4 iopamol injection.
At the same time, on May 14, 2020, the State Food and Drug Administration announced the launch of the consistency evaluation of injections, which greatly accelerated
the evaluation of injections.
as a generic of Class 4 iopamol injection.
At the same time, on May 14, 2020, the State Food and Drug Administration announced the launch of the consistency evaluation of injections, which greatly accelerated
the evaluation of injections.
When the fifth batch of centralized procurement volume catalogue was announced, iodixanol injection and iohexol injection that met the conditions for centralized procurement were included and implemented around October 2021; The third iopamol injection that meets the conditions for centralized procurement has also been included in the seventh batch of centralized procurement and will be implemented
around November this year.
around November this year.
Centralized procurement of contrast agents in countries
Iohexol injection and iodixanol injection are the main varieties of the contrast agent market, and the combined market share of both has exceeded 40% since 2014, reached 51.
6% in 2020, and declined to 36.
94%
in the first half of 2022.
6% in 2020, and declined to 36.
94%
in the first half of 2022.
Iohexol injection has been occupying the "first brother" seat of contrast agent from 2013 to 2019, with a peak sales of more than 3.
8 billion yuan
in 2019.
The sales scale of this product declined for the first time in 2020, and its ranking dropped to second, and in the first half of 2022, it fell by 59.
85% due to the impact of centralized procurement, and its ranking fell to fourth
.
As the first winning bidder of this product, the market share of the original manufacturer General Electric increased from 34.
56% in 2021 to 47.
66% in the first half of 2022, but its sales fell
sharply.
8 billion yuan
in 2019.
The sales scale of this product declined for the first time in 2020, and its ranking dropped to second, and in the first half of 2022, it fell by 59.
85% due to the impact of centralized procurement, and its ranking fell to fourth
.
As the first winning bidder of this product, the market share of the original manufacturer General Electric increased from 34.
56% in 2021 to 47.
66% in the first half of 2022, but its sales fell
sharply.
Sales of terminal iohexol injection in public medical institutions in China (: 10,000 yuan)
Source: Minai.
com Competition Pattern of Drug Terminals in China's Public Medical Institutions
com Competition Pattern of Drug Terminals in China's Public Medical Institutions
The sales scale of iodixanol injection has maintained a rapid growth trend since 2013, surpassing iohexol injection for the first time in 2020 to rank first in the market, exceeding 4.
7 billion yuan in 2021, and the product is no longer beautiful after being included in centralized procurement, plummeting 57.
90% in the first half of 2022, losing the first throne
.
After the selection, the market share of Yangzijiang Pharmaceutical's product rose to 29.
49% in the first half of 2022, surpassing General Electric to rank first in the market; The product was approved on August 17, 2020, and its market share increased from zero to 13.
70%.
7 billion yuan in 2021, and the product is no longer beautiful after being included in centralized procurement, plummeting 57.
90% in the first half of 2022, losing the first throne
.
After the selection, the market share of Yangzijiang Pharmaceutical's product rose to 29.
49% in the first half of 2022, surpassing General Electric to rank first in the market; The product was approved on August 17, 2020, and its market share increased from zero to 13.
70%.
Sales of terminal iodixanol injection in public medical institutions in China (: 10,000 yuan)
Source: Minai.
com Competition Pattern of Drug Terminals in China's Public Medical Institutions
com Competition Pattern of Drug Terminals in China's Public Medical Institutions
The sales of iopafenol injection in 2021 exceeded 1 billion yuan, and the sales in the first half of 2022 still had a bright growth of 20.
04%, with the implementation of the seventh batch of centralized mining, and there is a precedent of iohexol and iodixanol, and the follow-up performance is not optimistic
.
04%, with the implementation of the seventh batch of centralized mining, and there is a precedent of iohexol and iodixanol, and the follow-up performance is not optimistic
.
Sales of terminal iopamol injection in public medical institutions in China (: 10,000 yuan)
Source: Minai.
com Competition Pattern of Drug Terminals in China's Public Medical Institutions
com Competition Pattern of Drug Terminals in China's Public Medical Institutions
11 varieties have been evaluated, and Hengrui, Kelun, and Beite have won the first imitation
Up to now, 11 varieties of contrast agents have passed or are deemed to have passed the consistency evaluation
.
Among them, Hengrui Pharmaceutical and Beilu Pharmaceutical have 5 varieties have been evaluated, Kelun Pharmaceutical and Sitaili each have 3 varieties have been evaluated, and Chia Tai Tianqing, Yangtze River Pharmaceutical and Nanjing Chia Tai Tianqing each have 2 varieties have been evaluated
.
.
Among them, Hengrui Pharmaceutical and Beilu Pharmaceutical have 5 varieties have been evaluated, Kelun Pharmaceutical and Sitaili each have 3 varieties have been evaluated, and Chia Tai Tianqing, Yangtze River Pharmaceutical and Nanjing Chia Tai Tianqing each have 2 varieties have been evaluated
.
Comparison agent evaluation
Source: Minai.
com China Declaration Progress (MED) database
com China Declaration Progress (MED) database
There are 6 companies evaluating iodixanol injection, 4 companies evaluating iopamol injection and 3 companies of iohexol injection, and these three varieties have been included in the collective procurement
.
Gadolinium butrol injection, gadolinated acid glucosamine injection and gadolinium acid disodium injection have only been evaluated by 2 enterprises, and have not yet reached the conditions
for centralized procurement.
.
Gadolinium butrol injection, gadolinated acid glucosamine injection and gadolinium acid disodium injection have only been evaluated by 2 enterprises, and have not yet reached the conditions
for centralized procurement.
The five varieties were exclusively evaluated, namely Poppy Ethyl Iodine Oil Injection and Iodoxol Injection of Hengrui Pharmaceutical, Iodoxamide Injection of Beite Pharmaceutical, Gadolinium Glumine Injection of Hokuriku Pharmaceutical, and Gadoterol Injection of Kelun Pharmaceutical
.
.
Since the beginning of this year, a total of 6 contrast agent products have been approved for marketing in China, of which the first generic drug accounts for 3, including Hengrui Pharmaceutical's gadolinium butrol injection, Kelun Pharmaceutical's gadolinol injection, Beite Pharmaceutical's iopromide injection, and Hokuriku Pharmaceutical's gadolinium butrol injection is the second domestic one
.
.
Since 2022, domestic contrast agents have been approved
Source: Minai.
com China Declaration Progress (MED) database
com China Declaration Progress (MED) database
It is worth noting that CR Shuanghe is also actively making efforts, and the octafluoropropane lipid microsphere injection declared by it as a domestic agent has been approved for marketing by the State Food and Drug Administration, which is the first time that similar products have been approved for marketing in China, which is used for those whose conventional echocardiography development is not clear enough to enhance the recognition
of left ventricular endomembrane boundaries.
According to Lansos' financial report, the global sales of the product in 2021 were about 233 million US dollars
.
of left ventricular endomembrane boundaries.
According to Lansos' financial report, the global sales of the product in 2021 were about 233 million US dollars
.
Data source: Minainet database, company announcements
Note: Minai.
com's "Drug Terminal Competition Pattern of Public Medical Institutions in China", the statistical scope is: China's urban public hospitals, county-level public hospitals, urban community centers and township health centers, excluding private hospitals, private clinics and village clinics; The above sales are calculated
based on the average retail price of the product at the terminal.
com's "Drug Terminal Competition Pattern of Public Medical Institutions in China", the statistical scope is: China's urban public hospitals, county-level public hospitals, urban community centers and township health centers, excluding private hospitals, private clinics and village clinics; The above sales are calculated
based on the average retail price of the product at the terminal.
